DETECT V – Detection of estrogen receptor and human epidermal growth factor receptor 2 using CELLSEARCH® CXC kit
F Meier-Stiegen, S Riethdorf, A Schramm, A Polasik, D Niederacher, B Rack, FA Taran, V Müller, W Janni, J Huober, T Fehm · Geburtshilfe und Frauenheilkunde · 2016 · Heft 10
Bibliografische Angaben
Zusammenfassung
Background: The prognostic relevance of the enumeration of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) is well known. Nevertheless, the predictive value of CTCs still remains unclear. The DETECT study concept evaluates the impact of CTCs on therapeutic decisions. Patients with hormone-receptor positive, HER2-positive MBC participating in DETECT V are randomized to a dual HER2 targeted therapy combined with either endocrine therapy or chemotherapy. Based on the expression of estrogen-receptor (ER) and Human Epidermal Growth Factor Receptor 2 (HER2) on detected CTCs, an “Endocrine Responsivene…
